Author Index of Volume 7, 1984

Ahn Y. S. 35
Alper Ch. A. 251

Bettens F. 273
Borel Y. 1, 19

Carpenter C. B. 43
Cochrane Ch. G. 263

Dayer J.-M. 387
Demczuk St. 387

Fontana A. 375

Geczy C. L. 321
Gemsa D. 291
Grob P. J. 375

Hahn B. H. 25
Hamann U. 291
Harrington W. J. 35
Hültner L. 291
Hugli T. E. 193
Hughes-Jones N. C. 143

Joncourt F. 273

Kaltmann B. 291
Kees U. 291
Kirchner H. 347
Krammer P. H. 291
Kristensen F. 273
Kubelka C. 291

Lachmann P. J. 143

Malorny U. 311
Michels E. 311
Miescher P. A. 69
Müller-Eberhard H. J. 91, 93, 163
Mylvaganam R. 35

Neumann Ch. 311

Pangburn M. K. 163
Parkman R. 59

Reinherz E. L. 9
Rosen F. S. 251

Schimpl A. 299
Schlossmann S. F. 9
Schreiber R. D. 221
Schwartz R. S. 3
Sorg C 311
Stadler B. M. 415
Strom T. B. 43

Walker Ch. 273
Wang Y. 273
Weck de A. L. 271, 273, 415

Index – 1984

actinomycin C 39
alkylating agents 76
anaphylatoxins 193–219
–, cell activation 207
–, conformational analysis 202
–, effect on vascular permeability 209
–, mediator release 213
–, models of active sites 205
–, potentiation in vivo 213
–, primary structure 196
–, pulmonary tissue response 211
androgens 39
anemia, severe aplastic 61, 83
antibodies, anti-idiotypic 25
anti-Ig 301
anti-lymphocyte globulin (ALG) 79
anti-T12 52
aplastic anemia 61, 83
Arthus vasculitis, the role of complement in 263
asparaginase 39
astrocytes 376
autoimmune disease
–, suppression 25
–, susceptibility to 251
–, treatment of 72
autoimmune hemolytic anemia 83
azathioprine 3, 37, 44, 75

B cell growth factor (BCGF) 277, 302
B cell proliferation, lymphokines 299
B lymphocytes, proliferation and differentiation 277
basophils 416
bone marrow transplantation 59
brain, lymphokines and the 375

C1 activation 152
C1q binding
–, IgG antibodies 148
–, IgM antibodies 151
C1q receptor 222
C3 165
C3 convertase 164, 167
–, cobra venom factor 176
C3 hemolytic activity 167
C3 receptors 225
C3a receptor 226
C3b 164, 168, 174
–, amplification 178
–, random deposition 169
C3b receptor (CR1) 180
C3e receptor 237
C5 98
C5 convertase 104, 180
C5a receptor 240
C5b-channel 113
C5b-9 channel 121
C6 101
C7 101
C7 dimer 109
C8 102
C8 receptor 110
C9 103
cell cycle, cytofluometry 273
–, migration inhibitory factors 311
cell passage, from G1a into G1b phase 274
chemotaxis, lymphokines inducing 326
chlorambucil 39
chronic active hepatitis 86
colchicine 39, 79
collagenase 392, 396
–, control of production 397
–, PGE_2 production 399
colony stimulating factor (CSF) 293
complement, alternative pathway 163
–, –, activation of 154
–, –, reaction sequence 156
complement,
–, Arthus vasculitis 263
–, classical pathway 147
–, decay accelerating factor 164
–, experimental disease models 263–270
–, Factor B 164
–, Factor D 164
–, Factor H 164
–, Factor I 164
–, glomerulonephritis 263
–, immune complex disease 263
–, immunologic synovitis 263
–, inherited deficiencies 251
–, properdin 164
complement receptors 221–249
corticosteroids 47, 72
CR1 (immune adherence receptor) 228
CR2 232
CR3 233
cyclophosphamide 3, 37
cyclosporin A 49, 77
cytokines 387–413
cytotoxic immunosuppressive agents 75

danazol 79
decay accelerating factor 171, 181
–, complement 164
–, paroxysmal nocturnal hemoglobinuria 183
dexamethasone 277, 281

factor B, complement 164, 173
factor D, complement 164

factor H, complement 165, 179
factor I, complement 164, 173, 179
fibrin, delayed-type hypersensitivity 330

gammaglobulin, high-dose, intravenous 40
genetic diseases 64
glioblastoma 378
glomerulonephritis, the role of complement in 263
glucocorticoids 37

H receptor 238
hematopoietic stem cells 61
human peripheral blood lymphocytes, synchronization of 277
hydroxyurea 277

idiopathic thrombocytopenic purpura (ITP)
–, immunosuppressant therapy 35
–, splenectomy 36
Ig, secretion in proliferating B cells 306
IgE binding factor 419
IgE synthesis, in vitro 418
IgG, megadoses of 80
immune adherence receptor (CR1) 228
immune complex disease, the role of complement in 263
immune deficiency, severe combined 59
immune interferon (IFN-γ) 292
immune thyroiditis 19
immunologic synovitis, complement 263
immunosuppressants, nonsteroidal 37
immunosuppressant therapy, ITP 35
immunosuppression, nonspecific to specific 19
infections, susceptibility to 251
inflammation 387
interferons 308, 347–374
–, antiproliferative and anti-tumor effects 363
–, antiproliferative effect on lymphocytes 360
–, antiviral effects 358
–, immunoregulation 360
–, producer cells 352
–, subtypes 352
interferon activity, MIF 317
interferon gamma (IFN-γ) 353
interleukin-1 (IL-1) 48, 274, 377, 394
–, rheumatoid arthritis 400
interleukin-2 (IL-2) 47, 274
IL-2/IL-2 receptor interaction 274
IL-2 production 274
IL-2 receptor expression 277
IL-2 therapy 281
interleukin-3 (IL-3) 416
irradiation, total body 62

lepromatous leprosy 281
leukemia 63
levamisole 80
lipopolysaccharides (LPS) 173
lymphocyte proliferation 273
–, natural inhibitors 277
lymphocyte proliferation "profile" 279
lymphocyte receptors 282
–, age-associated changes 282
lymphoid cells, activated in vitro 276
lymphoid irradiation, total 5
lymphokines 291, 299, 375
–, B cell proliferation 299
–, delayed type hypersensitivity 321–346
–, inducing chemotaxis 326
–, vascular permeability 325
lymphokine/lymphokine receptor interaction 277
lymphokine secreting T cells, frequency of 293

membrane attack complex (MAC) 93
MAC-inhibitor 104
MAC neoantigens 131
macrophage activating factor (MAF) 292
macrophage phenotypes 311
–, MIF responsiveness 313, 317
major histocompatibility complex (MHC) 255
mast cells 416
6-mercaptopurine 3, 19, 75
methotrexate 39, 76
migration inhibitory factors (MIF) 311, 313, 317, 328
–, cell cycle 311
–, interferon activity 317
monoclonal antibodies 275, 313
–, anti-lymphocyte 51
mononuclear cell factor (MCF) 393
multiple sclerosis 86
murine lupus nephritis 25
myasthenia gravis, experimental, the role of complement in 268

neoplastic disease 4
nerve growth factor 381

paroxysmal nocturnal hemoglobinuria (PNH) 183
–, CR1 function 183
–, decay accelerating factor 183
–, leukocytes 185
–, platelets 185
plasmapheresis 40
procoagulant activity 330
properdin 165, 178
–, complement 164
prostaglandin E_2 (PGE_2) 277, 390, 395
pure red cell anemia 83

receptors, corticosteroid 283
receptors, insulin 283
regulatory proteins, membrane-associated 180
renal allograft, rejection 52
renal transplantation 43

rheumatoid arthritis 84, 387, 391
–, interleukin-1 400

S-protein 104
serotonin 277
serum Factor I 171
serum Factor H 171
synthetic peptides 198
systemic lupus erythematosus 81

T cells, lymphokine secreting, frequency of 293
T cell activation antigens 275
T cell clones 292
T cell differentiation 9
T cell hybridomas 292
T cell malignant disease 15
T cell replacing factor (TRF) 306
T cell subsets 12
–, inducer function 12
–, regulatory effect 12
–, suppressor function 13
T cell surface antigens 11
T lymphocytes, human 9
T lymphocyte subsets 11
thymic hormones 284
thymocytes 10
tolerogen 19
total body irradiation 62
transferrin 275
transferrin receptor 275
transplantation, bone marrow 59
transplantation, haploidentical 65
triggered enzyme cascades 144
tubular poly C9 114

vinblastine 38
vincristine 39

zymosan-C3b complex 168